Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146893 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study for Repurposing RET Inhibitors
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT07146893 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 7 participants.
The verdict
NCT07146893, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
Interventions
- DRUG Selpercatinib
- OTHER Strength Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-02-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146893
The ClinicalTrials.gov registry entry for NCT07146893 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selpercatinib is the first listed.
NCT07146893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07146893 about?
NCT07146893 is a clinical study titled "Feasibility Study for Repurposing RET Inhibitors". The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
What is the current status of trial NCT07146893?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2026-02-26. Estimated completion is 2028-02-23.
What interventions are being tested in trial NCT07146893?
The interventions under investigation include: Selpercatinib (DRUG), Strength Assessment (OTHER).
Who is sponsoring clinical trial NCT07146893?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.